424 related articles for article (PubMed ID: 24920841)
1. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for minimal change disease in adults: long-term follow-up.
Bruchfeld A; Benedek S; Hilderman M; Medin C; Snaedal-Jonsdottir S; Korkeila M
Nephrol Dial Transplant; 2014 Apr; 29(4):851-6. PubMed ID: 24121763
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
Basu B; Mahapatra TK; Mondal N
Pediatrics; 2015 Jul; 136(1):e132-9. PubMed ID: 26101364
[TBL] [Abstract][Full Text] [Related]
4. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
6. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
7. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series.
Maas RJ; Deegens JK; Beukhof JR; Reichert LJ; Ten Dam MA; Beutler JJ; van den Wall Bake AWL; Rensma PL; Konings CJ; Geerse DA; Feith GW; Van Kuijk WH; Wetzels JF
Am J Kidney Dis; 2017 May; 69(5):637-646. PubMed ID: 28089478
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
Taguchi S; Ohtake T; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
[TBL] [Abstract][Full Text] [Related]
9. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
[TBL] [Abstract][Full Text] [Related]
11. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
Kimata T; Hasui M; Kino J; Kitao T; Yamanouchi S; Tsuji S; Kaneko K
Am J Nephrol; 2013; 38(6):483-8. PubMed ID: 24296765
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
[TBL] [Abstract][Full Text] [Related]
13. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.
Takei T; Itabashi M; Moriyama T; Kojima C; Shiohira S; Shimizu A; Tsuruta Y; Ochi A; Amemiya N; Mochizuki T; Uchida K; Tsuchiya K; Nitta K
Nephrol Dial Transplant; 2013 May; 28(5):1225-32. PubMed ID: 23239834
[TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
[TBL] [Abstract][Full Text] [Related]
15. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome.
Sawara Y; Itabashi M; Kojima C; Tabata H; Kamei D; Kawanishi K; Moriyama T; Sugiura H; Tsukada M; Takei T; Ogawa T; Yoshida T; Arai J; Uchida K; Tsuchiya K; Nitta K
Clin Nephrol; 2009 Jul; 72(1):69-72. PubMed ID: 19640390
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.
Iwabuchi Y; Takei T; Moriyama T; Itabashi M; Nitta K
Medicine (Baltimore); 2014 Dec; 93(29):e300. PubMed ID: 25546674
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
Papakrivopoulou E; Shendi AM; Salama AD; Khosravi M; Connolly JO; Trompeter R
Nephrology (Carlton); 2016 Oct; 21(10):893-900. PubMed ID: 26860320
[TBL] [Abstract][Full Text] [Related]
18. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
Munyentwali H; Bouachi K; Audard V; Remy P; Lang P; Mojaat R; Deschênes G; Ronco PM; Plaisier EM; Dahan KY
Kidney Int; 2013 Mar; 83(3):511-6. PubMed ID: 23325085
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
Hoxha E; Stahl RA; Harendza S
Clin Nephrol; 2011 Aug; 76(2):151-8. PubMed ID: 21762648
[TBL] [Abstract][Full Text] [Related]
20. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.
Niu XL; Hao S; Wang P; Zhang W; Guo GM; Wu Y; Kuang XY; Zhu GH; Huang WY
Biomed Rep; 2016 Aug; 5(2):237-242. PubMed ID: 27446549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
